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Hepatic encephalopathy (HE) is a common complication of cirrhosis 
manifested by a range of neuro-psychiatric abnormalities and associated with 
significantly increased mortality, particularly in patients requiring acute 
hospitalization.1 Prognosis of acutely decompensated cirrhosis is dependent 
on the number and type of associated organ failures.2 Indeed, in cirrhotic 
patients with HE, not only is the occurrence of other organ failures associated 
with higher mortality rates, but the presence of HE in patients with multiorgan 
dysfunction adds to the risk of death suggesting that HE is prognostically 
important in this cohort of patients.1 However, patients with severe HE are 
difficult to study and consequently clinical trials in this patient population are 
rare. Therefore, we welcome this recent randomized clinical trial published in 
JAMA from Rahimi et al. who suggest that polyethylene glycol (PEG) may be 
more effective in cirrhotic patients with acute HE compared with the current 
gold-standard, lactulose.3 
 
Lactulose is widely available, inexpensive and is the standard of care for 
patients with HE despite a lack of high-quality robust placebo-controlled 
randomized controlled clinical trial data.4 More recently, the use of the non-
absorbable antibiotic Rifaximin has shown promise, initially approved for 
secondary prophylaxis and also demonstrating benefit in the treatment of 
overt HE but is less cost-effective as initial therapy.5-7 Rahimi et al. compared 
the administration of 4L of PEG, a commonly used purgative for bowel 
preparation for colonoscopy, against lactulose for the treatment of patients 
with cirrhosis admitted to hospital with an acute episode of HE. The study was 
based on the hypothesis that a rapid catharsis of the gut using PEG may be 
more effective than lactulose at clearing the bowel of toxins such as ammonia. 
The most outstanding findings were greater improvement in HE at 24 hours 
(based on objective scoring) and more rapid resolution of HE in patients 
receiving PEG therapy compared with lactulose. The study also reported a 
potential reduction in the hospital length of stay, which did not reach statistical 
significance. HE is not a homogenous condition, often with non-specific 
neurological symptoms and concomitant disorders, which makes these 
studies more difficult. One of the innovative solutions to study the mental state 
was their use of the HESA scoring system, which serves to objectify 
assessments and avoid bias.8   
 
The pathophysiology of HE is complex and incompletely understood. Multiple 
factors have been implicated including systemic inflammation, oxidative 
stress, genetic factors and altered gut microbiome.9 However, 
hyperammonaemia remains central to pathogenesis, although evidence 
directly correlating ammonia levels with severity of HE is limited.9 The data 
from Rahimi et al. are the first to show that ammonia levels in these acute HE 
cirrhotic patients is massively increased (mean 159 (+/- 70) μmol/L). Although 
the variability is high, these levels are seen in patients with severe acute liver 
failure at risk of brain herniation.10 Lactulose resulted in greater reductions but 
the changes in ammonia in the two groups are difficult to interpret as only a 
single measurement was made following initiation of therapy. Furthermore, 
ammonia was measured only in a small proportion of patients and the 
variation was massive, limiting attribution of cause effect relationship. 
Nevertheless, rapid ‘gut cleansing’ improved HE faster indicating the 
importance of the gut/liver/brain axis in the pathogenesis of HE.  
 
They correctly identify some weaknesses, most notably that it involves a 
relatively small cohort of patients (25 in each arm) from a single center, which 
makes the data prone to possible statistical errors. It was interesting to note 
that PEG treatment was safe and well tolerated with no deterioration of fluid or 
electrolyte status. Although the patients reportedly favored PEG therapy, any 
practical issues of managing this acute treatment on the hospital ward when 
significant gut catharsis is achieved in patients with altered conscious state 
are not described. PEG patients, not surprisingly, experienced more diarrhoea 
but the number of bowel actions achieved to assess adequate response to 
lactulose is not reported. Furthermore, patients treated with Rifaximin were 
excluded from this study. This may have helped to preserve the integrity of 
the treatment arms in a study of this small size and avoid confounding 
variables but also suggest that patients with more severe background HE may 
be missing from the study population. Rifaximin may be more expensive but is 
well tolerated. Given its reported efficacy for treatment and prophylaxis of HE 
in addition to lactulose, it would be interesting to explore in future studies the 
comparative benefit of PEG or Rifaximin as well as the role of combination 
therapies in treating acute HE. It is also worth noting that although patients in 
each treatment group were generally quite similar, there were a greater 
proportion of patients in the PEG arm whose HE was precipitated by non-
adherence with previous lactulose therapy. The significance of this is 
uncertain and would require a larger patient population to elucidate further, 
but raises the possibility that the lactulose group were a more refractory 
phenotype in terms of response to therapy.   
 
The importance of the study by Rahimi et al. goes beyond the clinical findings. 
It highlights the scarcity of rigorous clinical trial data, particularly for acute 
treatment of episodic HE. There is an unmet need for new effective therapies 
for this group of patients. Several other agents have attracted interest with 
some promising results although data remain limited and preliminary. These 
include various therapeutic strategies, such as ammonia reduction using 
ornithine phenylacetate or glycerol phenylbutyrate; probiotics and non-
absorbable antibiotics to manipulate the gut microbiome; as well as novel 
approaches such as albumin infusions and albumin dialysis.4, 9 The study by 
Rahimi et al. will no doubt allow these other interventions to be tested in these 
acute situations by providing insight into the clinical and pathophysiological 
issues.  
 
Emerging clinical trial data have started to provide important new insights into 
the spectrum of the clinical problem with distinct phenotypes seen in patients 
with different types of HE.1 The approach used to treat minimal HE will be 
different to approaches to primary and secondary prophylaxis, which will be 
different, as shown by Rahimi et al. to cirrhotic patients with acute HE. In this 
era of personalized medicine, it may be that treatment should entail different 
targets or combinations depending on the patient’s clinical presentation and 
pathophysiology. Ultimately, studies such as this provide hope for the 
emergence of more treatment options for this challenging and significant 
clinical problem, for which PEG may be a useful part of our armamentarium. 
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